bioRxivBiochemistryPreprint
Destruction of DNA-binding proteins by programmable O'PROTAC: Oligonucleotide-based PROTAC
J. Shao, Y. Yan, D. Ding, D. Wang, Y. He, Y. Pan, W. Yan, A. Kharbanda, H.-y. Li, H. Huang
Abstract
DNA-binding proteins including transcription factors (TFs) play essential roles in gene transcription and DNA replication and repair during normal organ development and pathogenesis of diseases such as cancer, cardiovascular disease and obesity, deeming to be a large repertoire of attractive therapeutic targets. However, this group of proteins are generally considered undruggable as they lack an enzymatic catalytic site or a ligand binding pocket. PROteolysis-TArgeting Chimera (PROTAC) technology has been developed by engineering a bifunctional small molecule chimera to bring a protein of interest (POI) to the proximity of an E3 ubiquitin ligase, thus inducing the ubiquitination of POI and further degradation through proteasome pathway. Here we report the development of Oligonucleotide-based PROTAC (OPROTACs), a class of noncanonical PROTACs in which a TF-recognizing double-stranded oligonucleotide is incorporated as a binding moiety of POI. We demonstrate that OPROTACs of ERG and LEF1, two highly cancer-related transcription factors selectively promote degradation of these proteins and inhibit their transcriptional activity in cancer cells. The programmable nature of OPROTACs indicates that this approach is applicable to destruct other TFs. OPROTACs not only can serve as a research tool, but also can be harnessed as a therapeutic arsenal to target DNA binding proteins for effective treatment of diseases such as cancer.
- organism: human
- assay: protein structure
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeted Degradation of Transcription Factors by TRAFTACs: Transcription Factor Targeting Chimeras
K. Samarasinghe, S. Jaime-Figueroa, … C. M. Crews·bioRxiv·Oct 12, 2020
- OligoTRAFTACs: A Generalizable Method for Transcription Factor Degradation
K. T. G. Samarasinghe, E. An, … C. M. M. Crews·bioRxiv·Dec 20, 2021
- bioPROTACs as versatile modulators of intracellular therapeutic targets: Application to proliferating cell nuclear antigen (PCNA)
S. Lim, R. Khoo, … A. W. Partridge·Proceedings of the National Academy of SciencesPeer-reviewed·Mar 2, 2020
- Circular mRNA encoded PROTAC (RiboPROTAC) as a new platform for the degradation of intracellular therapeutic targets
Jiali Yang, Jiaojiao Sun, … Chijian Zuo·bioRxiv·Apr 22, 2022
- Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3
J. Hall, Z. Zhang, … M. Kortylewski·bioRxiv·Aug 1, 2023
- Direct-to-Biology Enables Rapid Identification of Potent FBXO22 Degraders
Carla Brown, Sarvatit Patel, … Vijayaratnam Santhakumar·bioRxiv·Mar 2, 2026